Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sensei Biotherapeutics Inc (SNSE)

Sensei Biotherapeutics Inc (SNSE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,650
  • Shares Outstanding, K 1,261
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,160 K
  • EBIT $ -25 M
  • EBITDA $ -23 M
  • 60-Month Beta 0.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -4.81
  • Number of Estimates 1
  • High Estimate -4.81
  • Low Estimate -4.81
  • Prior Year -5.40
  • Growth Rate Est. (year over year) +10.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.82 +46.04%
on 12/15/25
11.74 -2.73%
on 01/12/26
+2.87 (+33.57%)
since 12/12/25
3-Month
7.45 +53.29%
on 12/05/25
18.35 -37.77%
on 10/16/25
+0.16 (+1.42%)
since 10/10/25
52-Week
5.00 +128.40%
on 03/31/25
18.35 -37.77%
on 10/16/25
+1.17 (+11.41%)
since 01/10/25

Most Recent Stories

More News
Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics...

SNSE : 11.42 (-1.68%)
Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

BOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics...

SNSE : 11.42 (-1.68%)
Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

6-month progression-free survival (PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings – All clinical responses, including a complete response,...

SNSE : 11.42 (-1.68%)
Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics...

SNSE : 11.42 (-1.68%)
Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics...

SNSE : 11.42 (-1.68%)
Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

- Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei...

SNSE : 11.42 (-1.68%)
Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

BOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics...

SNSE : 11.42 (-1.68%)
Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

SNSE : 11.42 (-1.68%)
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

SNSE : 11.42 (-1.68%)
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

SNSE : 11.42 (-1.68%)

Business Summary

Sensei Biotherapeutics Inc. is a clinical-stage immunotherapy company. It is focused on the discovery and development of therapeutics for cancer. The company's product pipeline includes SNS-301, SNS-401 and SNS-VISTA. Sensei Biotherapeutics Inc. is based in BOSTON, Md.

See More

Key Turning Points

3rd Resistance Point 12.21
2nd Resistance Point 11.97
1st Resistance Point 11.70
Last Price 11.42
1st Support Level 11.19
2nd Support Level 10.95
3rd Support Level 10.68

See More

52-Week High 18.35
Fibonacci 61.8% 13.25
Fibonacci 50% 11.68
Last Price 11.42
Fibonacci 38.2% 10.10
52-Week Low 5.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar